Core Viewpoint - Keren Biotechnology-B (06990) has seen a stock increase of nearly 5%, currently trading at 436 HKD with a transaction volume of 88.67 million HKD, following the announcement of multiple clinical research results at the ESMO conference in Berlin from October 17 to 21, 2025 [1] Group 1: Clinical Research Results - The company's core product SKB264 was selected for two oral presentations at ESMO, demonstrating BIC potential in the treatment of EGFRm NSCLC in the 2L+ setting, with good safety profile; the indication was approved for market in October [1] - SKB264 showed significantly better results than chemotherapy for HR+/HER2- BC in the 2L+ treatment, with expectations for approval in 2026 [1] - Clinical data for the core product A166 was announced, showing that it outperformed T-DM1 in the treatment of HER2+ BC in the 2L+ setting, with this indication also approved for market in October [1]
港股异动 | 科伦博泰生物-B(06990)涨近5% 公司核心产品SKB264于ESMO上中选两项口头报告